We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · July 25, 2019

Pembrolizumab Plus Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

The Lancet Haematology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Haematology
Pembrolizumab Plus Pomalidomide and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma (KEYNOTE-183): A Randomised, Open-Label, Phase 3 Trial
Lancet Haematol 2019 Jul 18;[EPub Ahead of Print], MV Mateos, H Blacklock, F Schjesvold, A Oriol, D Simpson, A George, H Goldschmidt, A Larocca, A Chanan-Khan, D Sherbenou, I Avivi, N Benyamini, S Iida, M Matsumoto, K Suzuki, V Ribrag, SZ Usmani, S Jagannath, EM Ocio, P Rodriguez-Otero, J San Miguel, U Kher, M Farooqui, J Liao, P Marinello, S Lonial

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading